Skip to main content
. 2019;20(6):1809–1815. doi: 10.31557/APJCP.2019.20.6.1809

Table 3.

Factor Associated with Progressive or Recurrent to CIN2 or Worse

Variables N Progressive/ recurrent
CIN2+ (%)
Crude HR 95% CI P-value Adjusted HR 95% CI P-value
Age
< 35 yrs. 62 2 (3.2)
> 35 yrs. 125 18 (14.4) 4.86 (1.13-20.97) 0.034* 5.8 (1.34-25.08) 0.019*
Parity
Nulliparity 33 3 (9.1)
Multiparity 154 17 (11) 1.41 (0.41-4.84) 0.588
HIV infection
No 170 20 (11.8)
Yes 17 0 0
Smoking
No 184 20 (10.9)
Yes 3 0 0
Initial histology
LSIL 108 7 (6.5)
HSIL 79 13 (16.5) 2.8 (1.12-7.03) 0.028*
p16 IHC staining
Negative 96 4 (4.2)
Positive 91 16 (17.6) 4.65 (1.55-13.93) 0.006* 5.33 (1.77-16.01) 0.003*
Treatment
Observation 105 10 (9.5)
LEEP 79 9 (11.4) 1.27 (0.52-3.13) 0.6
Hysterectomy 3 1 (33.3) 4.42 (0.56-34.73) 0.158

CIN2+, cervical intraepithelial neoplasia 2 or worse; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excision procedure; LSIL, low-grade squamous intraepithelial lesion; p16 IHC, p16 protein-immunohistochemistry; * Significance at p-value less than 0.05; †, Student t-test; ‡, Chi-square test, §Fisher-exact test